NASDAQ: GLUEMonte Rosa Therapeutics Inc Stock
$5.47-0.07 (-1.26%)
Updated Apr 24, 2024
GLUE Price
$5.47
Fair Value Price
$1.60
Market Cap
$274.34M
52 Week Low
$2.44
52 Week High
$8.84
P/E
-2.08x
P/B
1.53x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$135.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.7
Operating Cash Flow
-$44M
Beta
1.81
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GLUE Overview
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company developing of novel small molecule precision medicines that use the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways. Monte Rosa Therapeutics was incorporated in 2019 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLUE ($5.47) is overvalued by 242.6% relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLUE ($5.47) is not significantly undervalued (242.6%) relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLUE due diligence checks available for Premium users.
Be the first to know about important GLUE news, forecast changes, insider trades & much more!
GLUE News
Valuation
GLUE fair value
Fair Value of GLUE stock based on Discounted Cash Flow (DCF)
Price
$5.47
Fair Value
$1.60
Overvalued by
242.60%
GLUE ($5.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLUE ($5.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLUE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.08x
Industry
15.69x
Market
41.27x
GLUE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.53x
Industry
5.86x
GLUE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLUE's financial health
Profit margin
Revenue
$0.0
Net Income
-$33.3M
Profit Margin
0%
GLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$303.8M
Liabilities
$124.5M
Debt to equity
0.7
GLUE's short-term assets ($236.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLUE's short-term assets ($236.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$29.6M
Investing
$14.3M
Financing
$25.2M
GLUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLUE vs Biotech Stocks
Monte Rosa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.